Quality of Life in Depression Scale

The Quality of Life In Depression scale is a disease specific patient-reported outcome which assesses the impact that depression has on a patient’s quality of life.[1]

It is a 34 item self rated[2] questionnaire which consists of dichotomous response questions, with the response being either True/Not True or Yes/No.[3] It is scored binomially (0-1) and high scores on the QLDS indicated a lower quality of life.[4]

Development

The QLDS was developed by Galen Research in 1992 and was funded by Lilly Industries.[5] It was developed in the United Kingdom.

The items in the QLDS were derived from statements made in qualitative interviews by 30 depressed or recently recovered patients. Further interviews were held with patients in order to assess whether the proposed scale had face and content validity.[6]

International use

Since its development, the QLDS has been adapted and validated in 12 languages other than UK English,[7] including Norwegian[3] and Spanish.[8] This has allowed the QLDS to be used in research and clinical studies worldwide.

Studies utilizing the QLDS include investigations into venlafaxine,[9] duloxetine[10][11][12] and bupropion.[13]

References

  1. ↑ Amir, Marianne; Lewin-Epstein, Noah; Becker, Gideon; Buskila, Dan (2002). "Psychometric Properties of the SF-12 (Hebrew Version) in a Primary Care Population in Israel". Medical Care. 40 (10): 918–28. doi:10.1097/00005650-200210000-00009. PMID 12395025.
  2. ↑ Doraiswamy, P. M.; Khan, Z. M.; Donahue, R. M.J.; Richard, N. E. (2002). "The Spectrum of Quality-of-Life Impairments in Recurrent Geriatric Depression". The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 57 (2): M134. doi:10.1093/gerona/57.2.M134.
  3. 1 2 Berle, J.Ø.; McKenna, S.P. (2004). "Quality of Life in Depression Scale (QLDS): Adaptation and evaluation of the psychometric properties of the Norwegian version". Nordic Journal of Psychiatry. 58 (6): 439–46. doi:10.1080/08039480410006070. PMID 16195087.
  4. ↑ Callaghan, Patrick; Khalil, Elizabeth; Morres, Ioannis; Carter, Tim (2011). "Pragmatic randomised controlled trial of preferred intensity exercise in women living with depression". BMC Public Health. 11: 465. doi:10.1186/1471-2458-11-465. PMC 3128029Freely accessible. PMID 21663696.
  5. ↑ McKenna, Stephen P.; Hunt, Sonja M. (1992). "A new measure of quality of life in depression: Testing the reliability and construct validity of the QLDS". Health Policy. 22 (3): 321–30. doi:10.1016/0168-8510(92)90005-V. PMID 10122731.
  6. ↑ Hunt, Sonja M.; McKenna, Stephen P. (1992). "The QLDS: A scale for the measurement of quality of life in depression". Health Policy. 22 (3): 307–19. doi:10.1016/0168-8510(92)90004-U. PMID 10122730.
  7. ↑ "Measures Database". Galen Research. Retrieved 22 October 2013.
  8. ↑ Cervera-Enguix, S; Ramírez, N; Girala, N; McKenna, S.P (1999). "The development and validation of a Spanish version of the quality of life in depression scale (QLDS)". European Psychiatry. 14 (7): 392–8. doi:10.1016/S0924-9338(99)00230-8. PMID 10683624.
  9. ↑ Baca Baldomero, Enrique; Cervera Enguix, Salvador; Grupo De Estudio, Teseo (2003). "Calidad de vida en pacientes con depresión tratados en Atención Primaria. Efectividad y seguridad de la venlafaxina retard" [Quality of life, in depressed patients in Primary Health Care setting. Effectiveness and safety of venlafaxine extended release]. Actas espanolas de psiquiatria (in Spanish). 31 (6): 331–8. PMID 14639509.
  10. ↑ Detke, Michael J.; Lu, Yili; Goldstein, David J.; McNamara, Robert K.; Demitrack, Mark A. (2002). "Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression". Journal of Psychiatric Research. 36 (6): 383–90. doi:10.1016/S0022-3956(02)00060-2. PMID 12393307.
  11. ↑ Hudson, James I; Perahia, David G; Gilaberte, Inmaculada; Wang, Fujun; Watkin, John G; Detke, Michael J (2007). "Duloxetine in the treatment of major depressive disorder: An open-label study". BMC Psychiatry. 7: 43. doi:10.1186/1471-244X-7-43. PMC 2018694Freely accessible. PMID 17725843.
  12. ↑ Kornstein, Susan G.; Wohlreich, Madelaine M.; Mallinckrodt, Craig H.; Watkin, John G.; Stewart, Donna E. (2006). "Duloxetine Efficacy for Major Depressive Disorder in Male vs. Female Patients: Data From 7 Randomized, Double-Blind, Placebo-Controlled Trials". Journal of Clinical Psychiatry. 67 (5): 761–70. doi:10.4088/JCP.v67n0510. PMID 16841626.
  13. ↑ Dunner, David L.; Kwong, W. Jacqueline; Houser, Trisha L.; Richard, Nathalie E.; Donahue, Rafe M. J.; Khan, Zeba M. (2001). "Improved Health-Related Quality of Life and Reduced Productivity Loss After Treatment with Bupropion Sustained Release: A Study in Patients with Major Depression". Primary Care Companion to the Journal of Clinical Psychiatry. 3 (1): 10–16. doi:10.4088/PCC.v03n0103. PMC 181153Freely accessible. PMID 15014623.
This article is issued from Wikipedia - version of the 9/24/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.